The Report
“Dulaglutide (Type 2 Diabetes) – Forecast and Market Analysis to 2022″ is
now available at MarketOptimizer.org. Contact sales@marketoptimizer.org with Report name in subject line and
your contact details to purchase this report or get your questions answered.
Researcher has
released its new report, “Dulaglutide (Type 2 Diabetes) Forecast and Market
Analysis to 2022″. The type 2 diabetes market is mature and crowded with
inexpensive generics. Despite being marked by a late-stage pipeline filled with
me-too drugs, this market will undergo substantial growth between 2012 and
2022, more than doubling over this period. The main drivers of growth will be
the dramatic increase in disease prevalence and physicians’ efforts to delay
disease progression and reduce the costly burden of diabetic complications
through the use of combination therapies and novel branded drugs.
Dulaglutide
(LY2189265) is a long-acting GLP-1 analog being developed by Eli Lilly, currently
in Phase III clinical trials. Two Bristol-Myers Squibb’s medicines
(short-acting Byetta and long-acting Bydureon), Novo Nordisk’s long-acting
Victoza and Sanofi’s short-acting Lyxumia are marketed drugs in the same class
of treatments for type 2 diabetes.
Complete Report is available @ http://www.marketoptimizer.org/dulaglutide-type-2-diabetes-forecast-and-market-analysis-to-2022.html .
Scope
- Overview of type 2 diabetes,
including epidemiology, etiology, symptoms, diagnosis, pathology and
treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on
Dulaglutide including product description, safety and efficacy profiles as
well as a SWOT analysis.
- Sales forecast for Dulaglutide
for the top ten countries from 2012 to 2022.
- Sales information covered for the
US, France, Germany, Italy, Spain, the UK, Japan, Brazil, India and China.
Reasons to buy
- Understand and capitalize by
identifying products that are most likely to ensure a robust return
- Stay ahead of the competition by
understanding the changing competitive landscape for type 2 diabetes
- Effectively plan your M&A and
partnership strategies by identifying drugs with the most promising sales
potential
- Make more informed business
decisions from insightful and in-depth analysis of Dulaglutide performance
- Obtain sales forecast for
Dulaglutide from 2012-2022 in top ten countries (the US, France, Germany,
Italy, Spain, the UK, Japan, Brazil, India and China)
Buy the
copy of this Report @ http://www.marketoptimizer.org/contacts/purchase?rname=3440 .
1 Table of Contents 5
1.1 List of Tables 7
1.2 List of Figures 8
2 Introduction 9
2.1 Catalyst 9
2.2 Related Reports 10
3 Disease Overview 13
3.1 Etiology and Pathophysiology 13
3.1.1 Etiology 13
3.1.2 Pathophysiology 14
3.1.3 Prognosis 15
3.1.4 Quality of Life 16
3.2 Symptoms 16
4 Disease Management 18
4.1 Treatment Overview 18
4.1.1 Diagnosis and Referrals 18
4.1.2 Treatment Guidelines 19
5 Competitive Assessment 25
5.1 Overview 25
5.2 Strategic Competitor Assessment 26
6 Opportunity and Unmet Need 28
6.1 Overview 28
Inquiry before
buying this Report @ http://www.marketoptimizer.org/contacts/inquire-before-buying?rname=3440 . (Single
User License : US$ 3495 And Corporate User License : US$ 10485)
For
further information on “Dulaglutide (Type 2 Diabetes) – Forecast and Market
Analysis to 2022” report Contact sales@marketoptimizer.org / Call +1 888 391 5441.
